Liječnički vjesnik, Vol. 141 No. 3-4, 2019.
Pregledni rad
https://doi.org/10.26800/LV-141-3-4-14
1,3-Β-D-glucan in invasive fungal infection diagnostics – first Croatian experience
Sanja Pleško
; Klinički zavod za kliničku i molekularnu mikrobiologiju, Medicinski fakultet Sveučilišta u Zagrebu, KBC Zagreb
Milivoj Novak
; Odjel za pedijatrijsku intenzivnu medicinu, Klinika za pedijatriju, Medicinski fakultet Sveučilišta u Zagrebu, KBC Zagreb
Ernest Bilić
; Zavod za pedijatrijsku hematologiju, onkologiju i transplantaciju krvotvornih matičnih stanica, Klinika za pedijatriju, Medicinski fakultet Sveučilišta u Zagrebu, KBC Zagreb
Violeta Rezo Vranješ
; Klinički zavod za kliničku i molekularnu mikrobiologiju, Medicinski fakultet Sveučilišta u Zagrebu, KBC Zagreb
Jakša Babel
; Zavod za intenzivnu medicinu, Klinika za unutarnje bolesti, Medicinski fakultet Sveučilišta u Zagrebu, KBC Zagreb
Robert Baronica
; Odjel za anesteziologiju i intenzivno liječenje kirurških i uroloških bolesnika, Zavod za anesteziologiju i intenzivnu medicinu, Klinika za anesteziologiju, reanimatologiju i intenzivno liječenje, Medicinski fakultet Sveučilišta u Zagrebu, KBC Zagreb
Ivana Mareković
; Klinički zavod za kliničku i molekularnu mikrobiologiju, Medicinski fakultet Sveučilišta u Zagrebu, KBC Zagreb
Sažetak
Invasive fungal infections (IFI) are an important problem of modern medicine. The reason is growing population of immunocompromised patients and high morbidity and mortality of these infections. Timely
diagnosed IFI is of utmost importance because the delay of antifungal treatment has impact on treatment outcome. Cultivation as a conventional diagnostic method has low sensitivity, long duration and demands obtaining invasive samples. Therefore, in the last two decades fungal biomarkers are investigated for earlier and more sensitive diagnostics. 1,3-β-D-glucan (BDG) is a fungal biomarker in patients’ sera that enables detection of the following fungal pathogens: Candida spp., Aspergillus spp., Acremonium, Coccidioides immitis, Fusarium spp., Histoplasma capsulatum, Trichosporon spp., Sporotrix schenckii, Saccharomyces cerevisiae and Pneumocystis jirovecii. Low level and absence of BDG in the cell wall unables the detection of Cryptococcus spp. and order Mucorales with this test. High negative predictive value of BDG can be used when deciding to stop antifungal treatment and be a part of strategy for antifungal stewardship in intensive care units. In hematological patients BDG can be used as a screening method or as a part of diagnostic work-up when IFI is suspected. Reliability of test result is higher when two or more consecutive samples are positive. Influence of antifungal prophylaxis on BDG test results is still unclear. BDG kinetics and its relation to clinical outcome are still investigated. For pediatric population cut-off values for interpretation are still not defined, although many studies have been published investigating this issue. Although still not recommended by pediatric guidelines, this test can help in certain situations having in mind its limitations. BDG as a fungal marker represents the significant progress in IFI diagnostics. With simultaneous application of other diagnostic methods, exact interpretation and rational use, it can help earlier and more successful diagnostics and treatment of IFI.
Ključne riječi
INVASIVE FUNGAL INFECTIONS – diagnosis, drug therapy; ANTIFUNGAL AGENTS – therapeutic use; BETA-GLUCANS – blood; BIOMARKERS – blood; SENSITIVITY AND SPECIFICITY; CROATIA
Hrčak ID:
220212
URI
Datum izdavanja:
27.5.2019.
Posjeta: 3.689 *